睿知中国医院研究地图
候选清单

正在招募肺癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 8 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 20 岁 至 79 岁;性别:不限

    登记记录的入选字段

  2. Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;

    排除标准第 10 条

  3. Tumor size <= 2cm on preoperative CT scan;

    入选标准第 2 条

    Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio >= 0.25);

    入选标准第 4 条

  4. Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy);

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04937283,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patient aged 20-79 years old, both male or female;
  2. Tumor size <= 2cm on preoperative CT scan;
  3. Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;
  4. Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio >= 0.25);
  5. Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative (<= 5%);
  6. Intraoperative frozen section indicated the resection margins was free of tumor cells;
  7. Lung function could withstand both lung segmentectomy and lobectomy (FEV1 > 1.5L or FEV1% >= 60%);
  8. Eastern Cooperative Oncology Group, 0 to 2;
  9. Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.

排除标准:Exclusion Criteria:

  1. Radiological pure ground glass nodules (consolidation to tumor ratio < 0.25);
  2. The nodule is close to the lung hilus and is unable to perform segmentectomy;
  3. Intraoperative frozen section confirmed with micropapillary and solid subtype positive (> 5%);
  4. Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma;
  5. Preoperative imaging examination or EBUS indicated lymph node positive metastasis;
  6. Preoperative imaging examination revealed distant metastasis;
  7. Patients with severe damage to heart, liver and kidney function (grade 3 \~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit);
  8. Patients with other malignant tumors;
  9. Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy);
  10. Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;
  11. Those who have participated in other tumor-related clinical trials within three months;
  12. Those are not suitable for participating in trials according to investigator's assessment.

引自 ClinicalTrials.gov, NCT04937283, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04937283,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04937283